

The Effect of Rivaroxaban with Aspirin on Stroke Outcomes in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial

Purpose: Evaluation of the outcomes in patients with atherosclerosis (CAD, PAD) comparing treatment with rivaroxaban + aspirin to aspirin alone.

Trial Design: N= 27,395 patients with atherosclerosis. Rivaroxaban (2.5mg BID)+ aspirin (100 mg OD) vs aspirin alone in patient with atherosclerosis.

Primary Endpoints: combination of stroke, heart attack, CV death

	Primary Endpoint	P value
rivaroxaban 2.5 mg bid + aspirin vs aspirin	HR 0.76	<0.0001

The ischemic stroke rate was almost halved with rivaroxaban + aspirin vs. aspirin alone for patients with atherosclerosis.